Ats Medical, Inc. (ATSI) rated Buy with price target $3.25 by Feltl & Co.
Feltl & Co. rated Buy Ats Medical, Inc. (NASDAQ: ATSI) on 07/21/2008, when the stock price was $2.44.
Since then, Ats Medical, Inc. has gained 32.38% as of 08/20/2010's recent price of $3.23. If you would have followed this Feltl & Co.'s recommendation on ATSI, you would have gained 32.37% of your investment in 760 days.
ATS Medical, Inc. (ATS) develops, manufactures and markets medical devices for the treatment of structural heart disease. Product offerings include devices for the treatment of structural heart disease with a focus on heart valve therapy and the surgical treatment of cardiac arrhythmias. Heart valve therapy products consist of mechanical and tissue heart valves and heart valve repair products. Surgical arrhythmia therapy products consist of cryotherapy products for the ablation of cardiac arrhythmias. During the year ended December 31, 2008, sales of mechanical heart valves represented approximately 65% of the Company?s revenue.
Feltl and Company's Research Department is focused on micro to small market capitalization companies that are not widely covered by other research firms. Our research universe is focused and organized around the sectors of Technology, HealthCare, and Leisure/Consumer. Feltl and Company holds its research department to very high standards,
and strives to provide value- added investment ideas through sound fundamental analysis.
Feltl and Company's Research Department includes six senior analysts and one associate analyst with many years of investment analysis experience. Although we are focused on, and committed to, companies in the Upper Midwest, our reach extends from coast to coast. About half of the companies we cover are headquartered outside our "backyard."
Our analysts have significant industry experience and strive to know their companies inside and out. Through stringent analysis, they provide value by creating a disciplined application of company valuation, allowing our clients to make sound investment decisions.